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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objectives of this review are to assess:
1. the clinical efficacy of antihistamines in alleviating nasal symptoms (nasal congestion, rhinorrhoea and sneezing) in adults and
children suffering from a common cold;
2. the clinical efficacy of antihistamines in shortening the duration of the illness; and
3. the evidence on side effects of antihistamines and hence the risk to benefit considerations of this type of medication for the
common cold.
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B A C K G R O U N D
Description of the condition
The common cold is described as “an acute, self-limited inflamma-
tion of the upper respiratory tract mucosa that may involve any or
all of the nose, throat, sinuses, and larynx”. Symptoms include sore
throat, sneezing, blocked, and/or runny nose, headache, cough,
malaise and low-grade fever. Most of the population experience
at least one episode per year; these are usually self-limited and
resolve within a few days. (http://ce-preview.bmjknowledge.com/
monograph-proof/en-gb/html/252.html).
The incidence of acute upper respiratory tract infections (URTI),
such as the common cold, is difficult to define because of seasonal
and location variability. Children younger than one year com-
monly experience an average of six to eight episodes of URTI but
this figure decreases to three to four episodes per year by adult-
hood (Heikkinen 2003). The list of agents that cause the common
cold is large, but 66% to 75% of cases are due to 200 antigeni-
cally distinct viruses from eight different genera. The most com-
mon of these are the rhinoviruses (25% to 80% of cases), followed
by coronaviruses (10% to 20%), influenza viruses (10% to 15%)
and adenoviruses (5%) (Heikkinen 2003). The pathogenic mech-
anisms of the various respiratory viruses can be very different.
Rhinoviruses, the most common cause of the common cold, are
transmitted to susceptible individuals by direct contact or by
aerosol particles, beginning with deposition of the virus in the
anterior nasal mucosa or in the eye (via the lacrimal duct). The
viruses are then transported to the posterior nasopharynx by mu-
cociliary action. In the posterior nasopharynx, the viruses gain en-
try to the epithelial cells by binding to the specific receptors lo-
cated on the cells. Once inside the cell, the virus replicates rapidly
(Heikkinen 2003). Detectable histopathology that causes the as-
sociated ’cold and flu’ symptoms is lacking but it is hypothesised
that the host immune response plays a major role in rhinovirus
pathogenesis. Infected cells release interleukin-8 (IL-8), which is
a potent polymorphonuclear chemo-attractant. Concentrations
of IL-8 in secretions correlate proportionally with the severity of
common cold symptoms. Inflammatory mediators, such as kinins
and prostaglandins, may cause vasodilatation, increased vascular
permeability and exocrine gland secretion. These, together with
local parasympathetic nerve-ending stimulation, lead to common
cold symptoms (Heikkinen 2003; Papadopoulos 2000).
Symptoms develop one to two days after the infectionwith viruses,
peaking two to four days after inoculation and lasting on average
for seven to 10 days. Illness begins with a sore throat, which is
frequently the most bothersome of the early symptoms. This is
followed by nasal discharge, nasal congestion and sneezing, which
intensify over the next two to three days. Thirty percent of infected
individuals develop a cough, and 20% develop hoarseness, both
of which may persist up to a week. Systemic signs and symptoms
(for example, fever, malaise) are unusual and if they are present,
an alternative diagnosis should be considered (Heikkinen 2003).
Physical signs presented by patients include red nose, glistening
glassy appearance of nasal mucous membrane and dripping nasal
discharge (can be green/yellow in colour after 24 to 48 hours)
(Innes 2006).
Although not associated with fatal disease, the common cold is
associatedwith significantmorbidity.URTIs are estimated to cause
30% to 50% of time lost from work by adults and 60% to 80%
of time lost from school by children. Complications of common
cold include otitis media, sinusitis, lower respirator tract infections
(for example, bronchitis, pneumonia) and exacerbations of other
respiratory conditions (for example, asthma) (Innes 2006).
Description of the intervention
H1-receptor antagonists are a diverse group of drugs which possess
the ability to inhibit various histaminic actions. Principally they
act to prevent histamine-receptor interaction through competition
with histamine for histamine receptors, rather than inhibiting his-
tamine release. Consequently, they are helpful therapeutically in
preventing histaminic actions such as allergic rhinitis and allergic
skin conditions (Mann 1989; Pearlman 1976; Rossi 2010).
This class of drugs is divided into two groups: sedating and non-
sedating.
• Sedating antihistamines were the first generation of
antihistamines. They are associated with various adverse events
largely because of their propensity to cross the blood brain barrier
and their cholinergic activity causing symptoms of drowsiness
and reduced concentration, as well as dry mouth, blurry vision
and urinary retention (Gonzalez 1998; Rossi 2010).
• Non-sedating antihistamines or second-generation
antihistamines are lipo-phobic and pass the blood brain barrier to
a much lesser extent. They have the advantage of a lack of central
nervous system (CNS) and cholinergic effects (Gonzalez 1998).
How the intervention might work
There is no vaccination or cure for the common cold and treat-
ment therefore focuses on alleviating symptoms. Infection caused
by a virus leads to the dispersion of cytokines resulting in further
immune cell recruitment. Cytokines and other mediators induce
skin redness and temperature, nasal congestion, rhinorrhoea, wa-
tery eyes and sneezing (Heikkinen 2003; Papadopoulos 2000). In
comparison, histamine is involved in type 1 hypersensitivity reac-
tions (a type of allergic reaction,mediated by IgE) alongwith other
chemicals, and acts on the H1-receptor to contribute to symp-
toms like itchy skin, sneezing, red/watery eyes and rhinorrhoea,
as described above. As such, symptoms of infectious rhinitis (the
common cold) and allergic rhinitis (hypersensitivity type I) are
similar, although the mechanisms of pathogenesis are quite differ-
ent; antihistamines may play a minor role in alleviating symptoms
through potentially overlapping immune system mediators.
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Why it is important to do this review
In this review we will summarise evidence on the efficacy of anti-
histamines in monotherapy (first-generation and non-sedating) in
relieving nasal symptoms of the common cold. As antihistamines
are available over the counter in many countries, this review will
provide important information for consumerswho self treat. In ad-
dition, it will assist clinicians in making choices when prescribing
symptomatic treatment, in particular prescribing antihistamines
for the common cold. A rational use of antihistamines for the
common cold will aid in the reduction of unnecessary consump-
tion and unwanted adverse effects or complications from antihis-
tamines.
O B J E C T I V E S
The objectives of this review are to assess:
1. the clinical efficacy of antihistamines in alleviating nasal
symptoms (nasal congestion, rhinorrhoea and sneezing) in adults
and children suffering from a common cold;
2. the clinical efficacy of antihistamines in shortening the
duration of the illness; and
3. the evidence on side effects of antihistamines and hence the
risk to benefit considerations of this type of medication for the
common cold.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) on the treatment of the com-
mon cold with antihistamines, used in monotherapy.
Types of participants
Otherwise healthy adults (19 years or older) and children (new-
borns to 18 year of age) with common cold symptoms that meet
the following criteria:
1. recent onset of symptoms of runny and/or stuffy nose; and
2. sneezing with or without symptoms of headache and cough.
Participants will be excluded if they:
1. have allergic rhinitis;
2. have concurrent acute or chronic lower respiratory tract
infections, such as pneumonia, bronchitis, bronchiolitis;
3. have another chronic disease, atopic eczema, asthma, fever
(> 38 °C), sinusitis or exudative pharyngitis; or
4. take any other medication.
Types of interventions
Treatment with antihistamines (either first-generation or non-se-
dating) in monotherapy, which is administered either orally or
intra-nasally and is compared with a control group. The control
group can be either placebo or no treatment. We will also note
dosage, frequency of administration, duration of therapy and fre-
quency of assessment.
Types of outcome measures
Primary outcomes
1. The change in severity of overall symptoms of the common
cold (for example, absent, mild, moderate, severe).
2. The change in duration of overall symptoms of the
common cold (for example, days to resolution).
Secondary outcomes
1. The change in severity of individual symptoms, for
example, sneezing, nasal congestion, rhinorrhoea (for example,
absent, mild, moderate, severe).
2. The change in duration of individual symptoms, for
example, sneezing, nasal congestion, rhinorrhoea (for example,
days to resolution).
3. Side effects from using antihistamines.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Controlled Tri-
als (CENTRAL) latest issue, which contains the Cochrane Acute
Respiratory Infections (ARI) Group’s Specialised Register, MED-
LINE (1950 to present); EMBASE (1974 to present); LILACS
(1985 to present) and Biosis Previews (1985 to present).
We will use the following search strategy to search CENTRAL
andMEDLINE. We will combine the MEDLINE search strategy
with theCochraneHighly Sensitive Search Strategy for identifying
randomised trials in MEDLINE (Lefebvre 2011). We will adapt
the search strategy to search the other databases.
1 Common Cold/
2 common cold*.tw.
3 Nasal Obstruction/
4 ((runny or running*) adj2 nose*).tw.
5 ((nasal or nose*) adj3 (block* or discharge* or congest* or drip-
ping)).tw.
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6 coryza.tw.
7 (upper adj3 respiratory infection*).tw.
8 (upper adj3 respiratory tract infection*).tw.
9 Sneezing/
10 sneez*.tw.
11 urti.tw.
12 Rhinitis/
13 rhinit*.tw.
14 (rhinorrhea or rhinorrhea).tw.
15 Nasopharyngitis/
16 (nasopharyngit* or rhinopharyngit*).tw.
17 head cold*.tw.
18 Rhinovirus/
19 rhinovir*.tw.
20 coronavirus/ or coronavirus 229e, human/ or coronavirus nl63,
human/ or coronavirus oc43, human/
21 Coronavirus Infections/
22 coronavir*.tw.
23 exp influenzavirus a/ or exp influenzavirus b/
24 influenza virus*.tw.
25 influenzavirus*.tw.
26 Adenoviridae/
27 Adenovirus Infections, Human/
28 adenovirus*.tw.
29 or/1-28
30 exp Histamine Antagonists/
31 antihistamin*.tw,nm.
32 h1 receptor antagonist*.tw,nm.
33 loratadine.tw,nm.
34 ceterizine.tw,nm.
35 fexofenadine.tw,nm.
36 benadryl.tw,nm.
37 claritin.tw,nm.
38 zyrtec.tw,nm.
39 triaminic.tw,nm.
40 promethazine.tw,nm.
41 brompheniramine.tw,nm.
42 chlorpheniramine.tw,nm.
43 diphehydramine.tw,nm.
44 hydroxyzine.tw,nm.
45 or/30-44
46 29 and 45
Searching other resources
We will search the trials registers. We will also search reference
lists of the retrieved articles and contact experts and pharmaceuti-
cal companies to find any other potentially relevant published or
unpublished data. There will be no language, date or publication
restrictions.
Data collection and analysis
Selection of studies
Two review authors (AS, MVD) will independently screen the
titles and abstracts of citations.Wewill exclude trials failing tomeet
the inclusion criteria. We will retrieve articles identified which do
not have an abstract or have a limited abstract and assess them
for inclusion. A third review author (ADS) will be consulted if
disagreements are not resolved by discussion.
Data extraction and management
Two review authors (AS,MVD)will independently extract data by
using a pre-designed data extraction form. We will try to contact
trial authors for additional data where necessary. A third review
author (ADS) will be consulted if disagreements are not resolved
by discussion.
Assessment of risk of bias in included studies
We will assess the risk of bias of the included studies using the
criteria outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). Two review authors (AS, MVD)
will independently assess the risk of bias by assessing randomi-
sation sequence generation, allocation concealment, blinding, in-
complete outcome data, selective reporting and other potential
sources of bias. A third review author (ADS) will be consulted if
disagreements are not resolved by discussion. We will report the
results in the ’Risk of bias’ tables.
Measures of treatment effect
We will identify studies with the outcome measures as a global
evaluation of effectiveness (for example, complete relief, marked
relief, moderate relief, slight relief or no relief ) or a decrease in the
severity of individual common cold symptoms assessed by severity
scales. We will not extract data where individual severity scores
were added up and effectiveness was evaluated by comparing these
sum scores, as the clinical meaning of sum scores is unclear.
We will express dichotomous data as odds ratio (OR) or risk ratio
(RR) with 95% confidence intervals (CI). We will express con-
tinuous data as mean differences (MD) with a standard deviation
(SD). We will use a P value of less than 0.05 (P < 0.05) as our cut-
off for statistical significance. We will calculate the number needed
to treat for an additional beneficial outcome (NNTB) using the
OR and the average control event rate described in the relevant
studies, where applicable (Higgins 2011).
Unit of analysis issues
We will adjust for clustering if the unit of analysis is not the same
as the unit of randomisation, such as is the case for cluster-RCTs,
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using the methods described in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
We plan to contact trial authors for missing data where possible.
Otherwise wewill employ intention-to-treat (ITT) analysis, which
considers all missing data as treatment failure, when pooling the
data. We will compare the results of the ITT analysis with the
on-treatment analysis to assess the impact of missing data on the
overall outcome.
Assessment of heterogeneity
We will assess heterogeneity among studies in two ways. First, we
will assess heterogeneity at face value by comparing between stud-
ies the included population, the interventions and the reported
outcomes. Second, we will use the I2 statistic to assess the presence
of statistical heterogeneity (with > 50% as the cut-off value for
considerable heterogeneity). We will not pool data if considerable
heterogeneity exists at face value. We will use a fixed-effect model
for pooling data in the absence of statistical heterogeneity (as de-
scribed above). We will use a random-effects model whenever sta-
tistical heterogeneity is present (Higgins 2011).
Assessment of reporting biases
We will assess the completeness of reporting of outcomes of each
study in order to minimise reporting biases. We will do so by
contacting manufacturers to inquire about any unpublished data
or studies, if needed. We will also assess any potential conflict of
interest of funding and/or authors. We will perform funnel plot
analysis to assess potential publication bias if a sufficient number
of studies is available (i.e. more than 10).
Data synthesis
We will include in the meta-analysis the results from studies that
meet the inclusion criteria and report any of the selected outcomes.
We will summarise data statistically if available, sufficiently simi-
lar and of sufficient quality as described in Measures of treatment
effect. We will perform statistical analyses according to the statis-
tical guidelines of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analysis for children compared to
adults.
Sensitivity analysis
We will perform a sensitivity analysis to assess the impact of high
risk of bias on the outcome of the meta-analysis by gradually
adding studies with a high risk of bias to the pooled studies with
low risk of bias.
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